Protocol Ledger

NCT06631287 · Phase III · RECRUITING

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

Interventional Phase III clinical trial protocol NCT06631287 sponsored by Wes Ely in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-21 Enrollment: 550 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06631287
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)550 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06631287
Protocol FieldVerified Registry Value
NCT IdentifierNCT06631287
Consolidated Lead SponsorWes Ely
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment550 participants (ESTIMATED)
Registered Start Date2024-10-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI